Inclusion Criteria:
* Participants, including participants with a caregiver who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
* Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure.
* Medically stable patients as established by medical history and clinical examination at screening.
* Male or female participants \>=50 years of age (YOA) at the time of the first study intervention administration.
* Participants with documented history of coronary artery calcium (CAC) and two or more risk factors for cardiovascular disease.
* Participants with estimate glomerular filtration rate (eGFR) \>=45 mL/min/1.73m\^2.
* Participants who can undergo serial CCTA.
* Participants with no planned changes in medical therapies through the course of the study.
* Participants of non-childbearing potential may be enrolled in the clinical study.
* Participant of childbearing potential may be enrolled in the study if the participant:
* has practiced adequate contraception for at least 30 days prior to study intervention administration, and
* has a negative pregnancy test within 24 hours prior to the study intervention administration and prior to each CCTA, and
* has agreed to continue adequate contraception during the entire duration of the study and for 8 weeks after completion of the study.
Exclusion Criteria:
Cardiovascular conditions
* Prior atherosclerotic cardiovascular disease (ASCVD) event.
* History or planned coronary artery bypass grafting (CABG), any cardiovascular surgery, percutaneous coronary intervention (PCI), or valvular intervention.
* Heart failure with Class III or IV symptoms according to the New York Heart Association and/or unstable heart failure at the screening visit.
Other medical conditions
* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination (no laboratory testing required).
* Acute or unstable chronic conditions, clinically significant pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination and/or laboratory screening tests.
* Recurrent history or uncontrolled neurological disorders or any neuroinflammatory, congenital neurological conditions, encephalopathies, or seizures.
* Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the participant due to participation in the clinical study.
* Condition that in the judgment of the investigator would make intramuscular injection unsafe.
* Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
* History of malignancy \<=5 years, radiation therapy or systemic therapy prior to signing informed consent.
* Any history of dementia or any medical condition that moderately or severely impairs cognition.
Prior/Concomitant therapy
* Previous vaccination against Herpes Zoster (HZ) (investigational or licensed vaccine) and/or planned administration of vaccination against HZ during the study period other than the vaccine administered during the study.
* Previous vaccination with an RSV vaccine (investigational or licensed vaccine) and/or planned administration of an RSV vaccine during the study period other than the adjuvanted RSVPreF3 vaccine administered during the study.
* Use of any investigational or non-registered product other than the study intervention(s) during the period beginning 30 days before the first dose of study intervention(s) (Day -29 to Day 1), or their planned use during the study period.
* Administration of immunoglobulins or other blood products or plasma derivatives during the period starting 90 days before the study intervention or planned administration during the study period.
* Chronic administration of immune-modifying drugs and/or planned use of long-acting immune-modifying treatments at any time up to the end of the study.
* Planned administration/administration of a vaccine in the period starting 30 days before the first dose/each dose and ending 30 days after the last dose/each dose of study intervention(s) administration, with the exception of SARS-CoV-2 and inactivated seasonal influenza (flu) vaccine which can be administered up to 14 days before or 14 days after study intervention administration.
Prior/Concurrent clinical study participation
* Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention drug/invasive medical device.
* Contraindications to CCTA.
Other exclusion criteria
* Bedridden participants.
* Pregnant or lactating participant.
* History of current chronic alcohol consumption and/or drug abuse, based on investigator's judgment.
* Any study personnel or their immediate dependents, family, or household members.
